ライフサイエンスコーパス: MERS-CoV

1 MERS-CoV antibodies were detected in 13 of 24 (54%) case

2 MERS-CoV can infect multiple host species and cause seve

3 MERS-CoV infection during pregnancy may be associated wi

4 MERS-CoV infection failed to elicit robust IFN response,

5 MERS-CoV remains a high-threat pathogen identified by WH

6 MERS-CoV replication significantly upregulated C-type le

7 MERS-CoV seronegative and seropositive camels received a

8 MERS-CoV was first identified in June 2012 and has since

9 hermal calorimetry showed an approximate 1:1 MERS-CoV FP to Ca(2+) ratio, as opposed to an 1:2 SARS-C

10 e of AgNPs, giving detection limits of 1.53 (MERS-CoV), 1.27 (MTB), and 1.03 nM (HPV).

11 the transmission patterns underlying the 681 MERS-CoV cases detected in the Kingdom of Saudi Arabia (

12 ctious camels with active naturally acquired MERS-CoV infection, were co-housed with the vaccinated c

13 After MERS-CoV challenge, both vaccines conferred complete pro

14 There are no treatment options against MERS-CoV for humans or animals, and there are no large-s

15 otein induce potent immune responses against MERS-CoV and RABV.

16 -scale clinical trials for therapies against MERS-CoV.

17 it high neutralizing antibody titers against MERS-CoV.

18 re no efficacious drugs and vaccines against MERS-CoV, increasing its potential to cause a public hea

19 Although MERS-CoV generally causes subclinical or mild disease, i

20 miological investigation was conducted among MERS-CoV case patients (cases) and their household conta

21 tive risks of death and severe disease among MERS-CoV patients in the Middle East between 2012 and 20

22 in the distribution of DPP4 expression among MERS-CoV susceptible species, which might influence vari

23 ple CoVs, including SARS-CoV, SARS-CoV-2 and MERS-CoV.

24 is important for IKKepsilon activation, and MERS-CoV ORF8b suppresses type I IFN expression by compe

25 SARS-CoV and MERS-CoV FPs share a high sequence homology, and here, w

26 Both SARS-CoV and MERS-CoV have caused serious outbreaks and epidemics in

27 h two major outbreaks caused by SARS-CoV and MERS-CoV in the year 2002 and 2012, respectively.

28 st SARS-CoV-2 that also inhibit SARS-CoV and MERS-CoV in vitro We found that 17 of these inhibit SARS

29 Treatment of SARS-CoV and MERS-CoV infection is limited to providing supportive th

30 r a conserved epitope shared by SARS-CoV and MERS-CoV is a potential strategy for developing pan-coro

31 vancements made by studying the SARS-CoV and MERS-CoV outbreaks have provided a foundation for unders

32 developed in response to prior SARS-CoV and MERS-CoV outbreaks that can serve as resources for devel

33 The emergence of SARS-CoV and MERS-CoV provides evidence that coronaviruses are curren

34 bl2), as required for efficient SARS-CoV and MERS-CoV replication in vitro These data demonstrate tha

35 structurally characterized the SARS-CoV and MERS-CoV S glycoproteins in complex with neutralizing an

36 ronaviruses that are related to SARS-CoV and MERS-CoV were discovered in bats worldwide.

37 her beta-coronaviruses, such as SARS-CoV and MERS-CoV, and might become an important tool for structu

38 with the related coronaviruses SARS-CoV and MERS-CoV, and the vast experience with other common RNA

39 ighly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their prot

40 iratory tract illnesses, except SARS-CoV and MERS-CoV, which, in addition to mild illness can also be

41 The search terms also included SARS-CoV and MERS-CoV.

42 hCoVs 229E, NL63, OC43, HKU1, SARS-CoV, and MERS-CoV.

43 cus on seasonal coronaviruses, SARS-CoV, and MERS-CoV.

44 epitope was also recognized in SARS-CoV- and MERS-CoV-infected human leukocyte antigen DR2 and DR3 tr

45 ructures that were antiviral against IAV and MERS-CoV along with the filoviruses Ebola and Marburg an

46 f SKI genes inhibited replication of IAV and MERS-CoV.

47 mutations across the genome in both MHV and MERS-CoV.

48 coronavirus, mouse hepatitis virus (MHV) and MERS-CoV, encode 2',5'-phosphodiesterases (2',5'-PDEs) t

49 of evolutionary rates based on HCoV-OC43 and MERS-CoV.

50 y pathogenic coronaviruses such as SARS- and MERS-CoV into human circulation.

51 the significantly lower MERS-CoV titers and MERS-CoV and mRNA levels in challenged mice than those i

52 for highly pathogenic coronaviruses, even as MERS-CoV is spreading throughout the Middle East.

53 Incorporation of CD40L into rAd5-based MERS-CoV S1 vaccine targeting molecule and molecular adj

54 However, in vivo studies are limited because MERS-CoV cannot infect wild-type mice due to incompatibi

55 e East respiratory syndrome betacoronavirus (MERS-CoV) and found that 11 of the 22 residues in the pF

56 N retention signal by using chimeras between MERS-CoV M and the M protein of infectious bronchitis vi

57 ation of mouse DPP4 plays a role in blocking MERS-CoV infection.

58 Sera were screened by MERS-CoV nucleocapsid protein enzyme-linked immunosorben

59 in the RBD of representative human and camel MERS-CoV strains during the 2012-2015 outbreaks.

60 S proteins of representative human and camel MERS-CoV strains identified during the 2012-2015 outbrea

61 ion by divergent circulating human and camel MERS-CoV strains.

62 vaccines against circulating human and camel MERS-CoV strains.

63 ein with multiple changes derived from camel MERS-CoV strains.

64 These mutations severely compromised MERS-CoV infection into human lung-derived cells, but ha

65 ll shape the capacity to prevent and control MERS-CoV or new emerging disease transmission.

66 then analyzed the ability of mice to control MERS-CoV infection.

67 respiratory syndrome-associated coronavirus (MERS-CoV).

68 734) effectively inhibited MERS coronavirus (MERS-CoV) replication in vitro, and showed efficacy agai

69 with 90-day mortality and MERS coronavirus (MERS-CoV) RNA clearance using marginal structural modeli

70 ory syndrome and was named MERS coronavirus (MERS-CoV).

71 ceptor-binding domain from MERS coronavirus (MERS-CoV).

72 S-CoV), Middle East respiratory coronavirus (MERS-CoV) and SARS-CoV-2, have been linked back to vario

73 iddle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavi

74 iddle East respiratory syndrome coronavirus (MERS-CoV) are two highly transmissible and pathogenic vi

75 iddle East respiratory syndrome coronavirus (MERS-CoV) binds to cellular receptor dipeptidyl peptidas

76 iddle East respiratory syndrome coronavirus (MERS-CoV) cause significant morbidity and morality.

77 iddle East respiratory syndrome coronavirus (MERS-CoV) causes life-threatening disease.

78 iddle East respiratory syndrome coronavirus (MERS-CoV) causes severe and often lethal respiratory ill

79 iddle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 and is a highly pathogenic res

80 iddle East respiratory syndrome coronavirus (MERS-CoV) encode multifunctional papain-like proteases (

81 iddle East respiratory syndrome coronavirus (MERS-CoV) has been attributed to overcrowding, delayed d

82 iddle East respiratory syndrome coronavirus (MERS-CoV) has been shown to infect both humans and drome

83 iddle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain termination i

84 iddle East respiratory syndrome coronavirus (MERS-CoV) highlights the zoonotic potential of Betacoron

85 iddle East respiratory syndrome coronavirus (MERS-CoV) in household and healthcare settings, more dat

86 iddle East respiratory syndrome coronavirus (MERS-CoV) infection have been reported worldwide, with 6

87 iddle East respiratory syndrome coronavirus (MERS-CoV) infections are still unknown.

88 iddle East respiratory syndrome coronavirus (MERS-CoV) infections pose threats to public health world

89 iddle East respiratory syndrome coronavirus (MERS-CoV) initially emerged in 2012 and has since been r

90 iddle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic human coronavirus causi

91 iddle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic respiratory virus that

92 iddle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic respiratory virus that

93 iddle East respiratory syndrome coronavirus (MERS-CoV) is a lethal zoonotic pathogen endemic to the A

94 iddle East respiratory syndrome coronavirus (MERS-CoV) is a lethal zoonotic pathogen that was first i

95 iddle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus that since its

96 iddle East respiratory syndrome coronavirus (MERS-CoV) is a major emerging infectious disease with zo

97 iddle East respiratory syndrome coronavirus (MERS-CoV) is a novel virus that emerged in 2012, causing

98 iddle East respiratory syndrome coronavirus (MERS-CoV) is an emerging human pathogen that is the caus

99 iddle East respiratory syndrome coronavirus (MERS-CoV) is an emerging pathogen, first recognized in 2

100 iddle East respiratory syndrome coronavirus (MERS-CoV) is an important emerging pathogen that was fir

101 iddle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory

102 iddle East respiratory syndrome coronavirus (MERS-CoV) M protein.

103 iddle East respiratory syndrome coronavirus (MERS-CoV) multiplication results in reduced BECN1 levels

104 iddle East respiratory syndrome coronavirus (MERS-CoV) ORF4a accessory gene is expressed in yeast it

105 iddle East respiratory syndrome coronavirus (MERS-CoV) poses a threat to public health.

106 iddle East respiratory syndrome coronavirus (MERS-CoV) poses an ongoing threat to public health world

107 iddle East respiratory syndrome coronavirus (MERS-CoV) remains a significant threat for public health

108 iddle East respiratory syndrome coronavirus (MERS-CoV) targets the epithelial cells of the respirator

109 iddle East respiratory syndrome coronavirus (MERS-CoV) utilizes dipeptidyl peptidase 4 (DPP4) as an e

110 iddle East respiratory syndrome coronavirus (MERS-CoV) vaccines.

111 iddle East respiratory syndrome coronavirus (MERS-CoV) with eukaryotic proteins that may be potential

112 iddle East respiratory syndrome coronavirus (MERS-CoV), and human CoV 229E (HCoV-229E).

113 iddle East respiratory syndrome coronavirus (MERS-CoV), and the most recently emerged SARS-CoV-2.

114 iddle East respiratory syndrome coronavirus (MERS-CoV), encode a papain-like protease (PLpro) that po

115 iddle East respiratory syndrome coronavirus (MERS-CoV), from less pathogenic coronaviruses.

116 iddle East respiratory syndrome coronavirus (MERS-CoV), Mycobacterium tuberculosis (MTB), and human p

117 iddle East respiratory syndrome coronavirus (MERS-CoV), the spike (S) protein is the main determinant

118 iddle East respiratory syndrome coronavirus (MERS-CoV), two other highly pathogenic coronavirus spill

119 iddle East respiratory syndrome coronavirus (MERS-CoV).

120 iddle East respiratory syndrome coronavirus (MERS-CoV).

121 le Eastern respiratory syndrome coronavirus (MERS-CoV).

122 iddle East respiratory syndrome coronavirus (MERS-CoV).

123 iddle East respiratory syndrome coronavirus (MERS-CoV).

124 iddle East respiratory syndrome coronavirus (MERS-CoV).

125 iddle East respiratory syndrome coronavirus (MERS-CoV).

126 iddle East respiratory syndrome coronavirus (MERS-CoV).

127 iddle East respiratory syndrome coronavirus (MERS-CoV).IMPORTANCE Genetic recombination is often demo

128 iddle East respiratory syndrome coronavirus (MERS-CoV); however, development of effective and safe hu

129 % fatalities and now spread to 27 countries, MERS-CoV poses a significant ongoing threat to global hu

130 M) and Middle East respiratory syndrome CoV (MERS-CoV) (EC(50) = 0.56 muM) with minimal cytotoxicity.

131 oV) or Middle East respiratory syndrome CoV (MERS-CoV) also use bacterial components to modulate infe

132 2) and Middle East respiratory syndrome CoV (MERS-CoV) within two decades(1-3).

133 CoV-2, Middle East respiratory syndrome CoV (MERS-CoV), bat CoV HKU5 expressing the SARS-CoV-1 spike,

134 V) and Middle East respiratory syndrome CoV (MERS-CoV).

135 a-CoVs Middle East respiratory syndrome-CoV (MERS-CoV) and SARS-CoV and the gamma-CoV infectious bron

136 SARS-CoV-2 as well as the related SARS-CoV, MERS-CoV and endemic human coronaviruses (HCoVs).

137 erefore, the activity of PLPs from SARS-CoV, MERS-CoV, and mouse hepatitis virus was evaluated agains

138 ays, and cytokine secretion during SARS-CoV, MERS-CoV, and SARS-CoV-2 infection.

139 ined almost identical results with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRps.

140 coronavirus infection (SARS-CoV-2, SARS-CoV, MERS-CoV, seasonal coronaviruses).

141 f the FPs of S glycoproteins of 3 beta-CoVs, MERS-CoV, SARS-CoV, and MHV, and demonstrated that they

142 uch as camels, as well as humans from deadly MERS-CoV and RABV infections.

143 V-HKU1) as well as severe illness and death (MERS-CoV, SARS-CoV, SARS-CoV-2).

144 ng recombinant wild-type and ORF8b-deficient MERS-CoV further confirmed the suppressive role of ORF8b

145 at were persistently infected with DeltaORF5 MERS-CoV were resistant to superinfection by wildtype vi

146 Since RBD mutations occur in different MERS-CoV isolates and antibody escape mutants, cross-neu

147 e mutants, cross-neutralization of divergent MERS-CoV strains by RBD-induced antibodies remains unkno

148 We now demonstrate that in addition to DPP4, MERS-CoV binds to sialic acid (Sia).

149 monstrate that intracellular Ca(2+) enhances MERS-CoV wild-type (WT) PP infection by approximately 2-

150 MERS-CoV strains, as well as antibody escape MERS-CoV mutants.

151 during the 2012-2015 outbreaks, 5 MAb escape MERS-CoV mutants, and 2 live human MERS-CoV strains.

152 cts and depletion of macrophages exacerbates MERS-CoV-induced pathology and clinical symptoms of dise

153 y provides a structural framework explaining MERS-CoV attachment to sialoside receptors and identifie

154 cient adenoviral vectored vaccine expressing MERS-CoV spike protein, with further groups receiving co

155 No evidence of extrapulmonary MERS-CoV antigens were detected, including the kidney.

156 h reduction in 90-day mortality or in faster MERS-CoV RNA clearance.

157 d routinely collected epidemiologic data for MERS-CoV cases reported in Saudi Arabia during 1 January

158 via a conserved groove that is essential for MERS-CoV S-mediated attachment to sialosides and entry i

159 rst time that SIRT1 is a proviral factor for MERS-CoV replication and that ORF4a has a role in modula

160 rst time that SIRT1 is a proviral factor for MERS-CoV replication and that ORF4a has a role in modula

161 ggesting that SIRT1 is a proviral factor for MERS-CoV.

162 The role of Mincle for MERS-CoV-triggered cytokine/chemokine induction was esta

163 World Health Organization questionnaire for MERS-CoV case-control studies to assess risk factors for

164 While the cell surface receptor for MERS-CoV has been identified as dipeptidyl peptidase 4 (

165 r ability to act as functional receptors for MERS-CoV.

166 investigated whether Ca(2+) is required for MERS-CoV fusion by screening a mutant array in which E a

167 pothesis of bats as ancestral reservoirs for MERS-CoV.

168 r acts as a delayed RNA chain terminator for MERS-CoV polymerase complexes.

169 There are no approved treatments for MERS-CoV infection although a combination of lopinavir,

170 e, we applied technology previously used for MERS-CoV to produce a prefusion-stabilized SARS-CoV-2 sp

171 ental vaccine vector BNSP333, and the RABV G-MERS-CoV S1 fusion protein was efficiently expressed and

172 CD40-mediated specific responses to generate MERS-CoV S1 subunit-based vaccine.

173 As part of its viral genome, MERS-CoV encodes a papain-like protease (PLpro) that has

174 on prevention and control measures for human MERS-CoV infections.

175 rol studies to assess risk factors for human MERS-CoV seropositivity at a farm complex in Qatar.

176 Ab escape MERS-CoV mutants, and 2 live human MERS-CoV strains.

177 e mutations detected in representative human MERS-CoV strains from the 2012, 2013, 2014, and 2015 out

178 Our data illuminate MERS-CoV S sialoside specificity and suggest that select

179 DPP4 species-specific differences impacting MERS-CoV host range and better inform our understanding

180 aling species-specific differences impacting MERS-CoV host range.

181 ls expressing high levels of DPP4.IMPORTANCE MERS-CoV has pandemic potential, and it is important to

182 emergence and host susceptibility.IMPORTANCE MERS-CoV is a recently emerged zoonotic virus that is st

183 ORF8b was abundantly expressed in MERS-CoV-infected Huh-7 cells.

184 e wide range of disease severity reported in MERS-CoV-infected humans, which will aid in investigatin

185 ontribute to the proinflammatory response in MERS-CoV-infected macrophages.

186 Substitution of this motif resulted in MERS-CoV M leakage toward the plasma membrane.

187 ent could be attributed to Ca(2+) increasing MERS-CoV FP fusion-relevant membrane ordering.

188 induced clinical disease, strongly inhibited MERS-CoV replication in respiratory tissues, and prevent

189 ace Sia by neuraminidase treatment inhibited MERS-CoV entry of Calu-3 human airway cells, thus provid

190 cted humans, which will aid in investigating MERS-CoV disease pathogenesis.

191 only low-level incorporation of full-length MERS-CoV S into RABV particles.

192 ce treated with m336 prior to or post lethal MERS-CoV challenging were fully protected, compared to c

193 infection by divergent pseudotyped and live MERS-CoV strains, as well as antibody escape MERS-CoV mu

194 nge, as indicated by the significantly lower MERS-CoV titers and MERS-CoV and mRNA levels in challeng

195 These VHHs neutralize MERS-CoV or SARS-CoV-1 S pseudotyped viruses, respective

196 d and characterized type I IFN antagonism of MERS-CoV open reading frame (ORF) 8b accessory protein.

197 high-specificity, low-affinity attachment of MERS-CoV to sialoglycans during the preattachment or ear

198 ns designated S1(A) through S1(D) Binding of MERS-CoV to the cell surface entry receptor dipeptidyl p

199 e first autopsy performed on a fatal case of MERS-CoV in the world, which was related to a hospital o

200 ber 2019, 2499 laboratory-confirmed cases of MERS-CoV infection, including 858 deaths (34.3% mortalit

201 and between humans means that the drivers of MERS-CoV epidemics remain poorly characterized.

202 analyses to study the evolution dynamics of MERS-CoV among different host species with genomic data.

203 Cases occurring later in the emergence of MERS-CoV and among health-care workers were less serious

204 No serologic evidence of MERS-CoV transmission was found among 105 household cont

205 By sequencing the whole genome of MERS-CoV from persistently infected bat cells, we identi

206 coronaviruses, the spike (S) glycoprotein of MERS-CoV mediates receptor recognition and membrane fusi

207 Although the overall impact of MERS-CoV PLpro function is observed to be essential, dif

208 Despite frequent imports of MERS-CoV with camels from Africa, African lineages of ME

209 tein to study the mechanism of inhibition of MERS-CoV RdRp by RDV.

210 ant differences in FP Ca(2+) interactions of MERS-CoV and SARS-CoV FP despite their high sequence sim

211 As a result, the interface of MERS-CoV and human interferon-stimulated gene product 15

212 The introduction of MERS-CoV into the Republic of Korea by an infected trave

213 termined values of 50% lethal dose (LD50) of MERS-CoV for the 2 strains of mice, compared and correla

214 with camels from Africa, African lineages of MERS-CoV do not establish themselves in Saudi Arabia.

215 rhesus macaque and common marmoset model of MERS-CoV disease were analyzed.

216 vir treatment in a nonhuman primate model of MERS-CoV infection, the rhesus macaque.

217 Therefore, development of mouse models of MERS-CoV has been hampered by the fact that MERS-CoV doe

218 rhesus macaque and common marmoset models of MERS-CoV span the wide range of disease severity reporte

219 munity clusters, and nosocomial outbreaks of MERS-CoV continue to occur.

220 uces a new tool to probe the pathogenesis of MERS-CoV and related viruses through the removal of vira

221 e critical insights into the pathogenesis of MERS-CoV in humans.

222 tissues contribute to high pathogenicity of MERS-CoV.

223 We determined the prevalence of MERS-CoV infection, age-associated patterns of infection

224 autophagy but also reduce the replication of MERS-CoV up to 28,000-fold.

225 related activities may pose a higher risk of MERS-CoV infection, as may cross-border movements of cam

226 2,3-linked Sias and the predominant sites of MERS-CoV replication in the upper and lower respiratory

227 The first structure of MERS-CoV PLpro in complex with this domain exposed the i

228 Subsequently, the structure of MERS-CoV PLpro was solved to 2.4 A in complex with the C

229 lable vaccines or therapeutics, the study of MERS-CoV pathogenesis is crucial for its control and pre

230 Transmission of MERS-CoV was not documented in this investigation of mos

231 ansmission occurring during the treatment of MERS-CoV infections imported to Thailand.

232 rom MERS cases has hindered understanding of MERS-CoV pathogenesis.

233 ERS fatalities has hindered understanding of MERS-CoV pathogenesis.

234 (+) T cells, or macrophages has no effect on MERS-CoV replication in the lungs of infected mice.

235 nsgenic mice to study the effect of hDPP4 on MERS-CoV infection.

236 e closely related coronavirus, SARS-CoV-1 or MERS-CoV, despite previous zoonotic outbreaks.

237 Relative to the parental MERS-CoV, MERSMA viruses contained 13-22 mutations, incl

238 d the possibility that the zoonotic pathogen MERS-CoV, which also cocirculates in the same camel spec

239 arked pulmonary perivascular hemorrhage post-MERS-CoV challenge despite the observed protection.

240 pectrum RBD-based subunit vaccine to prevent MERS-CoV infection.

241 h prior to inoculation completely prevented MERS-CoV-induced clinical disease, strongly inhibited ME

242 domain of the MERS-CoV nucleocapsid protein (MERS-CoV N-NTD).

243 {CI}, .73-1.44]; P = .87) or with more rapid MERS-CoV RNA clearance (adjusted hazard ratio, 0.65 [95%

244 l or genetic manipulation, there was reduced MERS-CoV replication, suggesting that SIRT1 is a provira

245 tract tissues of humans and camels reflects MERS-CoV tropism.

246 for the inflammatory response in regulating MERS-CoV pathogenesis in vivo IMPORTANCE: The Middle Eas

247 for the inflammatory response in regulating MERS-CoV pathogenesis in vivo The Middle East respirator

248 The FSE-arch is conserved in the related MERS-CoV and is under purifying selection.

249 tion with the PDF2180 spike does not require MERS-CoV receptor DPP4 and antibodies developed against

250 stently infected cell culture model to study MERS-CoV-bat interactions.

251 While bat, camel, and human DPP4 support MERS-CoV infection, several DPP4 orthologs, including mo

252 me-CoV and Middle East respiratory syndrome (MERS-CoV).

253 Therefore, this study demonstrates that MERS-CoV RBD is an important vaccine target able to indu

254 MERS-CoV has been hampered by the fact that MERS-CoV does not replicate in commonly available mouse

255 Our findings indicate that MERS-CoV M protein localizes to the TGN because of the c

256 Our results indicate that MERS-CoV maintains the ability to replicate in bats with

257 These findings indicate that MERS-CoV variants with reduced neutralization sensitivit

258 Here, biophysical techniques revealed that MERS-CoV PLpro chiefly engages human ISG15 through its C

259 The MERS-CoV outbreak began in Saudi Arabia and has spread t

260 The MERS-CoV spike (S) protein binds to the cellular protein

261 The MERS-CoV-induced proinflammatory response was evaluated

262 We identify a functional link between the MERS-CoV ORF4a proteins and the YDL042C/SIR2 yeast gene.

263 eloped a RABV-MERS vector that contained the MERS-CoV S1 domain of the MERS-CoV S protein fused to th

264 ivated rabies virus particles containing the MERS-CoV S1 protein induce potent immune responses again

265 ivated rabies virus (RABV) that contains the MERS-CoV spike (S) protein expressed on its surface.

266 icted to infection at the level of DPP4, the MERS-CoV receptor, we generated mice with humanized exon

267 Here, we co-expressed the MERS-CoV nonstructural proteins nsp5, nsp7, nsp8, and ns

268 accinated mice were fully protected from the MERS-CoV challenge, as indicated by the significantly lo

269 ting with negatively charged residues in the MERS-CoV FP region.

270 utant array in which E and D residues in the MERS-CoV FP were substituted with neutrally charged alan

271 lu-213 with alanine induced retention of the MERS-CoV M in the ER.

272 ic structure of the N-terminal domain of the MERS-CoV nucleocapsid protein (MERS-CoV N-NTD).

273 Pulmonary expression of the MERS-CoV receptor, dipeptidyl peptidase 4, was similar i

274 that contained the MERS-CoV S1 domain of the MERS-CoV S protein fused to the RABV G protein C terminu

275 Infections are initiated via binding of the MERS-CoV spike (S) glycoprotein to sialosides and dipept

276 ular localization analyses revealed that the MERS-CoV M protein is retained intracellularly in the tr

277 glycosylation site that acts as a barrier to MERS-CoV infection.

278 ating that RLR signaling also contributed to MERS-CoV-induced proinflammatory response.

279 ectedly more resistant than hDPP4+/- mice to MERS-CoV infection, as judged by increased LD50, reduced

280 Additionally, the resistance to MERS-CoV infection directly correlated with increased se

281 mouse model to analyze the host response to MERS-CoV infection using immunological assays and transc

282 ed drugs for this use for a fast response to MERS-CoV outbreaks.

283 By understanding the immune response to MERS-CoV we can develop targeted therapies to inhibit pa

284 idase 4 receptor, making mice susceptible to MERS-CoV infection and replication.

285 o evidence of the potential for RDV to treat MERS-CoV infections.

286 d high-resolution structures of the trimeric MERS-CoV S ectodomain in complex with G4, a stem-directe

287 BNSP333-S, expresses a full-length wild-type MERS-CoV S protein; however, it showed significantly red

288 To understand MERS-CoV engagement of sialylated receptors, we determin

289 flammatory cascade in human macrophages upon MERS-CoV infection.

290 ay with human erythrocytes and intact virus, MERS-CoV Sia-binding activity was assigned to S subdomai

291 for use in animals and humans in areas where MERS-CoV is endemic.

292 p, we inoculated 10 Jamaican fruit bats with MERS-CoV.

293 We infected cells from Eptesicus fuscus with MERS-CoV and maintained them in culture for at least 126

294 22% (95% CI: 18, 25) of those infected with MERS-CoV died.

295 pulmonary manifestations when infected with MERS-CoV would advance the field.

296 at cells that are persistently infected with MERS-CoV.

297 Upon inoculation with MERS-CoV, human DPP4 knockin (KI) mice supported virus r

298 d both vaccinated mice and control mice with MERS-CoV after adenovirus transduction of the human dipe

299 Nine camel workers with MERS-CoV antibodies and 43 workers without antibodies we

300 derstanding viral deISGylase activity within MERS-CoV and other CoVs.IMPORTANCE Coronaviruses, such a